HEPA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States...

Stats
Today's Volume	37 510.00
Average Volume	78 532.00
Market Cap	7.22M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.110
ATR14	$0.0210 (1.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Purcell Michael J.	Buy	50 000	Restricted Stock Units
2024-03-05	Purcell Michael J.	Buy	0
2024-02-19	Block Timothy M.	Buy	85 000	Stock Options
2024-02-19	Jacob Gary S	Buy	85 000	Stock Options
2024-02-19	Lbiati Kaouthar	Buy	85 000	Stock Options

INSIDER POWER
92.99
Last 96 transactions
Buy: 8 825 675 \| Sell: 984 166

Volume Correlation

Long: -0.05 (neutral)

Short: -0.34 (neutral)

Signal:(33.606) Neutral

Hepion Pharmaceuticals Correlation

10 Most Positive Correlations
ATCX	0.925
SYKE	0.923
RDUS	0.907
ICON	0.898
BRACU	0.898
SPRB	0.89
JFIN	0.89
BGXX	0.885
MESA	0.88
CYN	0.872

10 Most Negative Correlations
VERA	-0.896
ARDS	-0.879
LGHL	-0.848
AHPI	-0.843
TUEM	-0.838
HRMY	-0.835
SBBP	-0.834
VIEW	-0.833
GRPH	-0.821
LCAP	-0.817

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Hepion Pharmaceuticals Correlation - Currency/Commodity

-0.55
( weak negative )

-0.61
( weak negative )

0.00
( neutral )

-0.55
( weak negative )

-0.40
( neutral )

0.07
( neutral )

Hepion Pharmaceuticals Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-67 131.00 (0.00 %)
EPS:	$-12.32

Q3	2023
Revenue:	$0
Gross Profit:	$-18 500.00 (0.00 %)
EPS:	$-2.74

Q2	2023
Revenue:	$0
Gross Profit:	$-18 328.00 (0.00 %)
EPS:	$-3.68

Q1	2023
Revenue:	$0
Gross Profit:	$-18 037.00 (0.00 %)
EPS:	$-3.48

Financial Reports:

No articles found.

Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.